Entries by

Abcam delivers outstanding performance in new Biocompare antibody market report

Academic and industry scientists rank Abcam as their Overall Preferred Antibody Supplier Peer recognition of Best Antibody Specificity demonstrates success of Company’s ongoing efforts to help life science industry address global reproducibility crisis Cambridge, UK, 27 November 2019 – Today, Abcam plc, a global innovator in life science reagents and tools that support research, drug […]

Scientists poised to unlock their understanding of autophagy with new antibody-based insights

Improved understanding could influence future diagnostic and therapeutic approaches. World’s leading methods journal documents use of key antibody, developed as part of Abcam – University of Ottawa collaboration. 25 November 2019, Cambridge, UK – Abcam is excited to announce its involvement in a ground-breaking methodology paper published today in Nature Methods, describing a new technique […]

Abcam agrees to acquire Expedeon’s Proteomics and Immunology business, expanding offerings into the fast-growing conjugation segment

Acquisition of leading protein conjugation technologies and products with wellknown industry brands, including Lightning-Link® and CaptSureTM Complementary to Abcam’s existing antibody and multiplex growth strategy, with high customer overlap Acquisition expected to be accretive from the first full year of ownership (FY21)1 and to deliver a ROIC (pretax) ahead of the Group’s WACC by the […]

Abcam and BrickBio announce a partnership to incorporate conjugation-ready sites into recombinant antibodies across Abcam’s portfolio

Cambridge, UK – Nov. 8, 2019 — Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce a strategic partnership with BrickBio, experts in site-specific protein modification and a Tiger Gene portfolio company, covering the use of BrickBio’s proprietary platform for introducing conjugation-ready sites into antibodies and other proteins […]

Engineered knockout cell lysates for reproducible proteomic analysis

Cambridge, UK, 7th November 2019 – Abcam’s new engineered knockout cell lysates enable proteomic studies by providing researchers with “true negative” controls. Acquiring reliable off-the-shelf knockout mouse models or cell lines that match specific experimental requirements can be challenging, and often need to be sourced directly from individual researchers or labs. Abcam’s newly-launched collection addresses […]